TABLE 2.
Injected with | Characteristics | Triglycerides | FFA | Cholesterol |
|||
---|---|---|---|---|---|---|---|
Total | Free | Esterified | |||||
mg/dl | mg/dl | mg/dl | |||||
Mttpf/f | Tamoxifen | WT | 53.2 ± 8.2 | 49.9 ± 5.2 | 76.8 ± 5.8 | 9.4 ± 1.7 | 67.4 ± 5.3 |
ERT2-villin-Cre;Mttpf/f | Tamoxifen | I-Mttp−/− | 31.3 ± 4.8 | 31.4 ± 3.1 | 42.6 ± 4.5 | 5.4 ± 3.1 | 37.1 ± 3.4 |
(−41.2)a | (−37.1)a | (−44.5)b | (−42.6) | (−45.0)b | |||
Abca1f/f | None | WT | 45.3 ± 8.3 | 46.3 ± 6.2 | 78.3 ± 6.2 | 10.6 ± 2.1 | 67.7 ± 6.2 |
Villin-Cre;Abca1f/f | None | I-Abca1−/− | 45.5 ± 4.1 | 49.4 ± 2.9 | 59.7 ± 3.8 | 6.9 ± 1.0 | 52.8 ± 2.8 |
(−0.5) | (+6.7) | (−23.8)c | (−34.9) | (−22.0)b | |||
ERT2-villin-Cre;Mttpf/f;Abca1f/f | Oil | WT | 50.3 ± 7.9 | 47.7 ± 5.4 | 77.6 ± 6.0 | 8.8 ± 1.4 | 68.8 ± 5.1 |
ERT2-villin-Cre;Mttpf/f;Abca1f/f | Tamoxifen | I-DKO | 24.8 ± 7.0 | 26.3 ± 5.7 | 31.6 ± 6.7 | 3.5 ± 1.7 | 28.1 ± 5.5 |
(−50.7)a | (−44.9)a | (−59.3)b | (−60.2)c | (−59.1)b |
a p < 0.01.
b p < 0.001 compared with WT mice.
c p < 0.05.